Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

670 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Cost effectiveness of peginterferon alpha-2b plus ribavirin versus interferon alpha-2b plus ribavirin for initial treatment of chronic hepatitis C.
Siebert U, Sroczynski G, Rossol S, Wasem J, Ravens-Sieberer U, Kurth BM, Manns MP, McHutchison JG, Wong JB; German Hepatitis C Model (GEHMO) Group; International Hepatitis Interventional Therapy (IHIT) Group. Siebert U, et al. Gut. 2003 Mar;52(3):425-32. doi: 10.1136/gut.52.3.425. Gut. 2003. PMID: 12584228 Free PMC article. Clinical Trial.
Antiviral treatment initiation costs in chronic hepatitis C.
Siebert U, Wasem J, Rossol S, Sroczynski G, Aidelsburger P, Ravens-Sieberer U, Kurth BM, Manns MP, McHutchison JG, Wong JB. Siebert U, et al. Gut. 2005 Jan;54(1):172-3. Gut. 2005. PMID: 15591531 Free PMC article. No abstract available.
Effectiveness and cost-effectiveness of initial combination therapy with interferon/peginterferon plus ribavirin in patients with chronic hepatitis C in Germany: a health technology assessment commissioned by the German Federal Ministry of Health and Social Security.
Siebert U, Sroczynski G; German Hepatitis C Model GEHMO Group; HTA Expert Panel on Hepatitis C. Siebert U, et al. Int J Technol Assess Health Care. 2005 Winter;21(1):55-65. doi: 10.1017/s0266462305050075. Int J Technol Assess Health Care. 2005. PMID: 15736515 Review.
Using competence network collaboration and decision-analytic modeling to assess the cost-effectiveness of interferon alpha-2b plus ribavirin as initial treatment of chronic hepatitis C in Germany.
Siebert U, Sroczynski G, Wasem J, Greiner W, Ravens-Sieberer U, Aidelsburger P, Kurth BM, Bullinger M, von der Schulenburg JM, Wong JB, Rossol S. Siebert U, et al. Eur J Health Econ. 2005 Jun;6(2):112-23. doi: 10.1007/s10198-005-0280-7. Eur J Health Econ. 2005. PMID: 15902546
[Health economics of chronic infectious diseases: the example of hepatitis C].
Wasem J, Sroczynski G, Aidelsburger P, Buchberger B, Hessel F, Conrads-Frank A, Peters-Blöchinger A, Kurth BM, Wong JB, Rossol S, Siebert U. Wasem J, et al. Among authors: siebert u. Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz. 2006 Jan;49(1):57-63. doi: 10.1007/s00103-005-1190-7. Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz. 2006. PMID: 16341606 German.
670 results